Grant: Alliance Grants
University of Toronto
$50,000.00
Developing organ-on-a-chip models of COVID-19_x000d_
EF 2020-21
Résumé
We propose the development of human organ-on-a-chip models to study SARS-CoV-2 infection. The virus binds to its receptor, angiotensin-converting enzyme 2 (ACE2), which is abundantly expressed in epithelial and endothelial cells. At the early stages, the innate immunity mounts a non-specific response to SARS-CoV-2 and directs the adaptive immune response to eliminate the virus and prevent disease progression to severe stages. It is currently impossible to predict who will experience a mild vs severe disease. Here, we will develop lung- and kidney-on-a-chip devices that enable studies of coronavirus infection to answer these questions. Uniquely, in organ-on-a-chip devices we can assess the earliest innate immunity responses that occur hours after the virus infection. Our goal is to place the devices on the market quickly so other academic and industry researchers can use them effectively. Currently, all organ-on-a-chip devices are produced by graduate students and post-docs manually at UofT. The partner organization, uFluidix, will develop a procedure for device scale-up and a conduit for device placement on the market. Dr. Radisic has a significant previous experience in studying immune cells such as monocytes and macrophages in a biomimetic environment under flow. In Aim 1, we will develop a human-cell based platform to study epithelial response to SARC-CoV-2. In Aim 2, a system to study macrophage and neutrophil extravasation in response to coronavirus infection of the lung will be established in our flow based systems, termed AngioTube. In Aim 3, model of SARS-CoV-2 infection of the kidney will be established using the Topomembrane platform. All models will first be developed with CL2 coronaviruses 229E and NL63 that Dr. Radisic has access to in her laboratory. Infection with a live SARS-CoV-2 will be performed by a skilled post-doc from the laboratory of Dr. Zhang in the CL3 facility at the UofT. Assurance of project success is the support of the leading Canadian microfluidic device manufacturer, uFluidix, who have manufactured devices for over 1000 customers over the past 10 years, enabling us to get the devices to the market in an extremely fast time frame.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
555054-2020
Name nom
Radisic, Milica
Department département
Chemical Engineering and Applied Chemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Developing organ-on-a-chip models of COVID-19_x000d_
Keyword
NSERC
Application summary
We propose the development of human organ-on-a-chip models to study SARS-CoV-2 infection. The virus binds to its receptor, angiotensin-converting enzyme 2 (ACE2), which is abundantly expressed in epithelial and endothelial cells. At the early stages, the innate immunity mounts a non-specific response to SARS-CoV-2 and directs the adaptive immune response to eliminate the virus and prevent disease progression to severe stages. It is currently impossible to predict who will experience a mild vs severe disease. Here, we will develop lung- and kidney-on-a-chip devices that enable studies of coronavirus infection to answer these questions. Uniquely, in organ-on-a-chip devices we can assess the earliest innate immunity responses that occur hours after the virus infection. Our goal is to place the devices on the market quickly so other academic and industry researchers can use them effectively. Currently, all organ-on-a-chip devices are produced by graduate students and post-docs manually at UofT. The partner organization, uFluidix, will develop a procedure for device scale-up and a conduit for device placement on the market. Dr. Radisic has a significant previous experience in studying immune cells such as monocytes and macrophages in a biomimetic environment under flow. In Aim 1, we will develop a human-cell based platform to study epithelial response to SARC-CoV-2. In Aim 2, a system to study macrophage and neutrophil extravasation in response to coronavirus infection of the lung will be established in our flow based systems, termed AngioTube. In Aim 3, model of SARS-CoV-2 infection of the kidney will be established using the Topomembrane platform. All models will first be developed with CL2 coronaviruses 229E and NL63 that Dr. Radisic has access to in her laboratory. Infection with a live SARS-CoV-2 will be performed by a skilled post-doc from the laboratory of Dr. Zhang in the CL3 facility at the UofT. Assurance of project success is the support of the leading Canadian microfluidic device manufacturer, uFluidix, who have manufactured devices for over 1000 customers over the past 10 years, enabling us to get the devices to the market in an extremely fast time frame.